Market Scenario
Cancer is generally characterized by a deregulated and disorderedstromal and cellular explosion and reduced cell death. Biological therapy involves using a living organism substance which is either derived from the laboratory produced variations or from living organisms of the substances which are used to treat a specific disease. Biological therapies consist of interferons, interleukins, vaccines, and monoclonal antibodies. The therapy uses the immune system of the body directly or indirectly to fight against cancer. Market Research Future (MRFR) proclaims that the global Cancer Biological Therapy Market is slated to garner USD 82,276.8 million, grabbing a CAGR during the forecast period (2017-2023). Demand for biological therapies is favoring the market growth. Cancer is considered the second largest and the leading cause of death globally. Market Potential and Pitfalls The global cancer biological therapy marketis expanding at a sturdy rate owing to the intensified cancer survival rates, rising cancer healthcare facilities, and increased demand for advanced therapies like biological therapy,especially in the emerging nations. The side effects associated with biological therapy is less when compared to conventional treatment methods, which is the major factor behind the growth of the market. Side effects of conventional cancer treatment methods such as radiotherapy and chemotherapy include weekend immune system and loss of hair depending upon the phase and type of cancer.Biological therapy reduces the level of side effects compared to conventional methods and offersthe same amount of success rate for curing patients with first stage cancer. The high success rate and low level of side effects have fostered the market growth throughout the appraisal period. The market’s course is chiefly directed by the increased smoking population and changing lifestyle,especially in the Middle East & African regions. For instance, from 1990 to 2012, the smoking rate in Lebanon has increased by 500%. The market is also driven by the augmenting prevalence of various types of cancer, constant patent expiry of cancer drugs, rising impact of a biosimilar, and surging demand of targeted and biological drug therapy across the globe. On the contrary, the risks associated with the treatment and high cost ofcancerbiologicaltherapy are the top barriers considered to vitiate the market growth throughout the appraisal period. Moreover, the poor rate of healthcare insurance in the developing economies are likely to dampen the market growth over the years. Global Cancer Biological Therapy Market: Segmental Analysis The global cancer biological therapy market has been segmentedon the basis of phases, type, and end-users. By mode of phase, the global cancer biological therapy market has been segmentedinto phase I, phase II, and phase III. By mode of type, the global cancer biological therapy market has been segmented into interferons, monoclonal antibodies, cancer growth inhibitors, interleukins, colony-stimulating factors, and gene therapy. Among these, the monoclonal antibodies segment occupies a significant share in the global market. Monoclonal antibodies can target specific proteins on the cell surface, which has increased its adoption in cancer treatment. By mode of end-users, the global cancer biological therapy market has been segmented into cancer research centers, hospitals & clinics, and laboratories. Among these, the hospitals & clinics segment occupies the major share as a cancer treatment is performed in hospitals and clinics. Industry Updates Geographically, the cancer biological therapy market span across regions namely, Europe, North America,Asia Pacific, and the Middle East & Africa. Considering the global scenario, the North American region is considered to command the largest share. The growth is credited to the advanced technologies which are continuously on the rise in this region.With the presence of a number of vaccine manufacturers and cancer biological drugs, affordable treatment facilities, rising disposable income, and the rising number of health-insurance coverage, the market in this region is estimated to propel in the coming years. The European region occupies the second-largest share in the global market owing to the increased prevalence of cancer in this region. The market in this region is likely to propel owing to several factors such as the presence of elderly patient population, and increased development in cancer therapies. Moreover, the constantly evolving technologies in molecular biology, innovative approaches in technology, and sophistication in healthcare are some of the other factors likely to propel the market growth in this region. Industry Updates March 20, 2019: The immunotherapy program of the Northside Hospital Cancer Institute has planned to expand its treatment for acute lymphoid leukemia and other types of non-Hodgkins lymphoma. Competitive Dashboard The prominent players operating the global cancer biological therapy market are Celgene Corporation, Merck & Co. Inc., EnGeneIC Ltd, Novartis, ELI Lilly and Company, Bristol-Myers Squibb, Pfizer Inc., F. Hoffmann-La Roche AG, Amgen Inc., and others.
0 Comments
Market Scenario:
The global alopecia drugs market is presumed to expand at 6.92 % CAGR during the forecast period (2016-2022)owing to the changing lifestyle, asserts Market Research Future (MRFR). Alopecia is a chronic autoimmune disease that causes hair loss including face, body, and scalp. One of the major factors of hair loss being genetic. Hair loss caused due to alopecia can be restricted to a part of body, partial, or complete hair loss.Alopecia drugs have proven to be useful in treating hair loss both in males and females. The drugs prescribed by healthcare professionals depend on the type of alopecia, extent of hair loss, and age. Drivers and Constraints Impacting the Market: With changing lifestyle and change in the environmental conditions, the prevalence of alopecia is likely to increase.Hormonal disbalance increases the probability of chronic diseases such as depression, cancer, arthritis, and hypertension which eventually leads to hair loss among the middle to late-aged people.Growing consciousness of one’s personal appearance, high disposable income, and novel therapeutic options are some of the major factors propelling the market growth. Moreover, scalp and hair problems such as adverse effects of products with heavy chemical composition, pollution, and availability of numerous treatment solutions to fight such problems are estimated to impact the market positively.The advent of innovative drugs to treat alopecia and eradicate the side effects to conventional drugs can generate high revenues for several market players. On the flip side, failure of drugs due to emotional stress, the high cost of medication, and adverse effects of alopecia drugs are likely to retard the market growth in the coming years. Moreover, ample availability of counterfeit, low-cost and low-quality products are hampering the global market to a great extent. Competitive Dashboard: Sun Pharmaceutical Industries Ltd., Ranbaxy Laboratories Ltd, The Himalaya Drug Company, Johnson & Johnson, Cipla Inc., Taisho Pharmaceutical Holdings Co., Dr. Reddy’s Laboratories Ltd., and Merck & Co. Global Alopecia Drugs Market: Segmental Analysis:
Geographically, the alopecia drugs market span across regions namely North America, Europe, Asia Pacific, and Rest-of-the-World. Among all the regions, North America is estimated to lead the global market and is expected to hold the largest market share. The market is expected to touch 375 billion by the end of the review period owing to the high level of product innovation, emerging trends in the market, and changing formulations. Europe is presumed to hold the second position in the global market both in terms of revenue and market size.The growth is attributed to the growing prevalence of alopecia with the increasing aging population. Also, presence of major market players coupled with funding and investments by them in countries such as Italy, Germany, and the U.K. support the market growth in this region. Asia Pacific is considered to be one of the lucrative markets for alopecia drugs. The growth in this region is attributed to the large unmet clinical needs and continuously improving economy. Also, the consumption of alopecia drugs is expected to increase in this region, offering opportunities to the market players to expand their production base in the developing countries. Industry News: An article published in the International Journal of Dermatology statedthat a recent pilot study has found that novel combination therapy for female pattern hair loss was both effective and safe. Each woman took a capsule containing 25 milligrams of spironolactone and 0.25 mg of oral minoxidil once a day for 12 months.Each of the drugs, when taken separately, can prevent hair loss. When consumed together, they offer better results.
Market Overview: With the air pollution rising around the world, the number of asthma patients is also increasing. Therefore the market for the drugs necessary for its treatment is rising.Market Research Future (MRFR) has published a research report that envisions surge in the global anti-asthma drugs market with 5.94% CAGR (Compound Annual Growth Rate) between 2015 and 2022. In terms of cash, the market is expected to rise with the US $ 28.3 bn by the end of the forecast period. Observing the market structure, this report evaluates the future growth potential of the market and analyzesthe strategies of the key players in the market. It also follows the competitive developments such as joint ventures,new product developments, mergers and acquisitions, new product developments (R & D) in the market. According to this report, the key factors that drive this growth of this market include growing awareness of the benefits of modern drug therapy, the great potential of biologics, growth in patients due to increasing pollution, and problems arising from consumerism & unhealthy lifestyles.Constraints that can make the market growth hit a roadblock are the fear among leading drug brands regarding the loss of patents of leading brands, and increasing fragmentation of markets and generic penetration. Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/2353 The global Anti-Asthma Drugs Market has been segmented on the basis of drug class, route of administration, therapy, trigger, type, and lastly, region.On the basis of drug class, this market has been segmented into bronchodilators, corticosteroids, leukotriene antagonists, mast cell stabilizers, monoclonal antibody, and others. Bronchodilators have been further segmented into Key Players AstraZeneca PLC (UK), BoehringerIngelheim (Germany), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline PLC (UK), Merck & Co. Inc. (USA), Novartis International AG (Switzerland), Sunovion Pharmaceuticals Inc (USA), and Teva Pharmaceutical Industries (Israel). Segmentation:
The regional segmentation of the global anti-asthma drugs market segments the market into regional markets namely The Americas (North America & South America), Europe, Asia Pacific, the Middle East & Africa (MEA). Due to the availability of advanced medical facilities, North America is not only a bigger market than South America, but it is also the biggest market foranti-asthma drugs. In this region, the biggest country-wide market is the United States of America (USA). Many key players in the market are based here. Europe is the second largest market as it is also equipped with advanced medical facilities. The cream of the market in this region covers, like France, Germany, Italy, Spain,and the United Kingdom (UK) followed by the rest of Europe.The Asia Pacific is witnessing major newer cases due to greater screening and better health care facilities distribution. During the forecast period, this region is expected to emerge as the fastest growing market. The most important markets in this region are China, India, Japan, and South Korea, followed by the rest of Asia Pacific.The MEA region is a small market due to lack of awareness about anti-asthma, lack of education, lack of technological development, poor healthcare, and healthcare not considered a priority by most governments. Market Overview:
The Global Crohn’s Disease Market is expected to exhibit a solid 3% CAGR over the forecast period from 2016 to 2022, according to a new research report from Market Research Future (MRFR). The Global Crohn’s Disease Market is mainly driven by the growing awareness about Crohn’s and other inflammatory bowel diseases.Crohn’s disease is an inflammatory bowel disease that can affect any part of the gastrointestinal tract. Around 1.4 million Americans suffer from either Crohn’s disease or ulcerative colitis, signifying its growing prevalence and threat. The growing awareness about inflammatory bowel diseases is likely to be a major driver for the global Crohn’s disease market over the forecast period. Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/2344 The increasing demand for biologics to treat Crohn’s disease is likely to be a prominent feature of the global Crohn’s disease market over the forecast period. Biologics offer a more comprehensive solution to the incidence of Crohn’s disease, including safer action and more effective eradication of the disease. Increasing interest in biologics and their high potential in curing a number of diseases has resulted in a growing demand for biologics for the treatment of Crohn’s disease. On the other hand, the high cost of current treatments has held back the global Crohn’s disease market and is likely to remain a significant restraint on the market in the short term, till biologics can be developed on an industrial scale and brought into mass circulation. Competitive Analysis: Leading players in the Global Crohn’s Disease Market include
In April 2019 Researchers at the University of Michigan Medical School published findings wherein they developed a mouse model for studying the etiology of Crohn’s disease and the role genetics plays in it. This research found that the development of Crohn’s disease is driven by a specific interaction between a microbe and a gene, which could prove to be the basis for effective treatments to Crohn’s disease in the coming years. Segmentation: The Global Crohn’s Disease Market is segmented on the basis of procedure, drugs, and region. By procedure, the global Crohn’s disease market is segmented into colonoscopy, flexible sigmoidoscopy, CT, MRI, capsule endoscopy, double-balloon endoscopy, and small bowel imaging. Colonoscopy, flexible sigmoidoscopy, and computed tomography (CT) are likely to remain the leading procedures used to diagnose Crohn’s disease. By drugs, the global Crohn’s disease market is segmented into anti-diarrheal drugs, antibiotics, pain relievers, immune system suppressors, and anti-inflammatory drugs. Regional Analysis: North America is likely to dominate the global Crohn’s disease market over the forecast period due to the growing prevalence of the disease in North America, the growing awareness about Crohn’s disease and other inflammatory bowel diseases, and the rising establishment of genetic research facilities in the U.S. and Canada. Crohn’s disease is more prevalent in developed European and North American economies than in underdeveloped Asian or Latin American countries, leading to the former two regions accounting for the major shares in the global Crohn’s disease market over the forecast period. Large-scale availability of effective Crohn’s disease medication, easy linkup between genetic research and day-to-day healthcare sector operations, and the growing spending capacity of consumers in North America are likely to ensure the region’s dominance in the global Crohn’s disease market over the forecast period. In Asia Pacific, China is likely to be a major consumer for Crohn’s disease testing and medication over the forecast period. Market Insights:
The increasing demand for biologics to treat Crohn’s disease is likely to be a prominent feature of the global Crohn’s disease market over the forecast period. Biologics offer a more comprehensive solution to the incidence of Crohn’s disease, including safer action and more effective eradication of the disease. Increasing interest in biologics and their high potential in curing a number of diseases has resulted in a growing demand for biologics for the treatment of Crohn’s disease. Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/2344 The Global Crohn’s Disease Market is expected to exhibit a solid 3% CAGR over the forecast period from 2016 to 2022, according to a new research report from Market Research Future (MRFR). The Global Crohn’s Disease Market is mainly driven by the growing awareness about Crohn’s and other inflammatory bowel diseases.Crohn’s disease is an inflammatory bowel disease that can affect any part of the gastrointestinal tract. Around 1.4 million Americans suffer from either Crohn’s disease or ulcerative colitis, signifying its growing prevalence and threat. The growing awareness about inflammatory bowel diseases is likely to be a major driver for the global Crohn’s disease market over the forecast period. On the other hand, the high cost of current treatments has held back the global Crohn’s disease market and is likely to remain a significant restraint on the market in the short term, till biologics can be developed on an industrial scale and brought into mass circulation. Competitive Analysis: Leading players in the Global Crohn’s Disease Market include
The Global Crohn’s Disease Market is segmented on the basis of procedure, drugs, and region. By procedure, the global Crohn’s disease market is segmented into colonoscopy, flexible sigmoidoscopy, CT, MRI, capsule endoscopy, double-balloon endoscopy, and small bowel imaging. Colonoscopy, flexible sigmoidoscopy, and computed tomography (CT) are likely to remain the leading procedures used to diagnose Crohn’s disease. By drugs, the global Crohn’s disease market is segmented into anti-diarrheal drugs, antibiotics, pain relievers, immune system suppressors, and anti-inflammatory drugs. Regional Analysis: North America is likely to dominate the global Crohn’s disease market over the forecast period due to the growing prevalence of the disease in North America, the growing awareness about Crohn’s disease and other inflammatory bowel diseases, and the rising establishment of genetic research facilities in the U.S. and Canada. Crohn’s disease is more prevalent in developed European and North American economies than in underdeveloped Asian or Latin American countries, leading to the former two regions accounting for the major shares in the global Crohn’s disease market over the forecast period. Large-scale availability of effective Crohn’s disease medication, easy linkup between genetic research and day-to-day healthcare sector operations, and the growing spending capacity of consumers in North America are likely to ensure the region’s dominance in the global Crohn’s disease market over the forecast period. In Asia Pacific, China is likely to be a major consumer for Crohn’s disease testing and medication over the forecast period. |